Cargando…
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
PURPOSE: Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100. METHODS: Patients with malignant solid tumors were assigned sequentially to one of te...
Autores principales: | Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909249/ https://www.ncbi.nlm.nih.gov/pubmed/24297683 http://dx.doi.org/10.1007/s00280-013-2361-0 |
Ejemplares similares
-
PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma
por: Ebrahim, Abdul Shukkur, et al.
Publicado: (2016) -
Unintended target effect of anti-BCL-2 DNAi
por: Ebrahim, Abdul Shukkur, et al.
Publicado: (2017) -
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
por: Rodrigueza, Wendi V., et al.
Publicado: (2014) -
Targeted Downregulation of MYC through G-quadruplex Stabilization by DNAi
por: Psaras, Alexandra Maria, et al.
Publicado: (2021) -
Deep Coupled Integration of CSAC and GNSS for Robust PNT
por: Ma, Lin, et al.
Publicado: (2015)